Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 4
March 26, 2012
- Bayer Yakuhin to Initiate Drug Use-Result Survey on 10,000 Patients for Xarelto
March 23, 2012
- Shionogi Submits PIIa Clinical Trial Application for OncoTherapy’s AMD Vaccine
March 23, 2012
- Ajinomoto Pharmaceuticals to Market Gastritis/Ulcer Treatment Marzulene from July
March 23, 2012
- Astellas Vice Deputy Chairman Ishii Says Company R&D Strategy Focused on Personalized Medicine
March 22, 2012
- India’s Ministry of Commerce and Industry Kicks Off “Brand India Pharma” Campaign
March 22, 2012
- BD Japan Seeking Further Partnerships with Japanese Companies: Pres. Harris
March 22, 2012
- MTPC, Novartis Revise Package Insert of Imusera/Gilenya in Response to Overseas Death
March 22, 2012
- MSD, BIKEN Sign Domestic Marketing Agreement for 3 Flu Vaccines
March 22, 2012
- Taiho Pharmaceutical Launches TS-1 in 4 Scandinavian Countries
March 22, 2012
- Acquisition by Lupin Improves Kyowa Pharmaceutical Industry’s Profitability: President Tsunoda
March 21, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 1
March 19, 2012
- Break of Day－Working to Optimize Settai Practices, Increase Financial Transparency: 2
March 19, 2012
- Nichi-Iko Definitely to Enter as Global Top-10 Generics Company within 4 Years: President Tamura
March 16, 2012
- Fuji-Keizai Predicts Japan’s Generics Market to Exceed ¥580 Billion in 2014
March 16, 2012
- All-Case PMS for Sutent Lifted: Pfizer
March 16, 2012
- Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
- Teva-Kowa, Taiyo, Nippon Kayaku Apply for Approval of Gran Biosimilar
March 15, 2012
- Shionogi Submits Clinical Trial Application in Europe for OncoTherapy’s Cancer Vaccine
March 15, 2012
- Nichi-Iko Makes Yakuhan Its Subsidiary, Acquiring 69% of Company’s Stock
March 15, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…